Shionogi

Japan screening massive drug compound libraries for new treatments

Wednesday, June 5, 2013 01:32 PM

The Global Health Innovative Technology Fund (GHIT Fund), a public-private partnership focused on Japanese R&D related to infectious disease, will make a series of agreements to screen compound libraries at Japanese pharmaceutical companies and research institutes for new treatments for malaria, tuberculosis and other afflictions.

More... »

Medicines Patent Pool collaborates with ViiV Healthcare

Friday, March 1, 2013 12:39 PM

The Medicines Patent Pool (MPP) has launched a collaboration with ViiV Healthcare—a joint venture of GlaxoSmithKline, Pfizer and Shionogi—to facilitate greater availability of critically needed medicines for children living with HIV.

More... »

Shionogi, ViiV Healthcare to commercialize and develop integrase inhibitor portfolio

Tuesday, October 30, 2012 11:19 AM

ViiV Healthcare, a global specialist HIV company based in the U.K., and Shionogi, a Japanese research-driven pharmaceutical company, have entered into an agreement substantially revising their integrase inhibitor relationship.

More... »

Shinogi’s Cuvposar reduced chronic severe drooling

Wednesday, January 25, 2012 04:15 PM

Therapeutics and Clinical Risk Management online journal published Shinogi’s promising results from two studies on Cuvposar, the first and only FDA-approved treatment to reduce chronic severe drooling in patients ages 3-16 with neurologic conditions associated with chronic drooling.

More... »

Shire partners with Shionogi to develop ADHD medicines

Friday, November 18, 2011 11:48 AM

Shire has entered into an agreement with Shionogi & Co. of Japan to co-develop and co-commercialize certain of Shire's Attention Deficit Hyperactivity Disorder (ADHD) medicines in Japan. Shionogi will pay a one time fee and share costs with Shire in exchange for rights to jointly co-develop and co-commercialize the products upon approval for the Japanese market. Specific terms of the agreement are not being disclosed. 

More... »

Graffinity Pharmaceuticals forms alliance with Shionogi

Wednesday, April 6, 2011 12:16 PM

Graffinity Pharmaceuticals has entered into a research collaboration with the Japanese pharmaceutical company Shionogi. As part of the agreement, Graffinity will receive technology access fees and payments for follow-up chemistry for the generation of various, new small molecule developments against a key drug target.

More... »